Fall River

Ask VT AI
View News Summary
  • Novo Nordisk launches a rival $56.50 bid to acquire U.S. obesity biotech Metsera, challenging Pfizer's existing agreement and sparking a bidding war over Metsera's promising GLP-1 pipeline.
  • Incyte advances multiple early-phase cancer trials with potential therapeutic breakthroughs, highlighting their strategic focus on oncology and rare diseases.
  • Zebra Technologies reports strong Q3 results, but margins decline and guidance raises concerns about execution and the company's shift to software and services.
20 days
USA flag

United States Politics

Discover the latest news, candidates, 
and key topics of US politics

Latest News
Ask VT AI
View News Summary
  • Novo Nordisk launches a rival $56.50 bid to acquire U.S. obesity biotech Metsera, challenging Pfizer's existing agreement and sparking a bidding war over Metsera's promising GLP-1 pipeline.
  • Incyte advances multiple early-phase cancer trials with potential therapeutic breakthroughs, highlighting their strategic focus on oncology and rare diseases.
  • Zebra Technologies reports strong Q3 results, but margins decline and guidance raises concerns about execution and the company's shift to software and services.
20 days
USA flag

United States Politics

Discover the latest news, candidates, 
and key topics of US politics

Most Reported By
News from Fall River